<i>In Vitro</i> Activity of Cefiderocol against Extensively Drug-Resistant Pseudomonas aeruginosa: CANWARD, 2007 to 2019
James A. Karlowsky, Andrew Walkty, Melanie Baxter, Heather J. Adam, Philippe Lagacé‐Wiens, Frank Schweizer, Denice C. Bay, Joseph P. Lynch, Michael R. Mulvey, George G. Zhanel
Abstract
After testing cefiderocol against a large collection of clinical isolates of highly antimicrobial-resistant Pseudomonas aeruginosa , we report that cefiderocol is active versus 97.4% of extensively drug-resistant (XDR) and 97.9% of multidrug-resistant (MDR) ( n = 771) isolates. These data show that cefiderocol may be a treatment option for infections caused by MDR and XDR P. aeruginosa .
Topics & Concepts
Pseudomonas aeruginosaBiologyMicrobiologyIn vitroComputational biologyBacteriaGeneticsAntibiotic Resistance in BacteriaAntibiotic Use and ResistanceAntibiotics Pharmacokinetics and Efficacy